Vaporization as a smokeless cannabis delivery system: A pilot study

被引:175
作者
Abrams, D. I. [1 ]
Vizoso, H. P.
Shade, S. B.
Jay, C.
Kelly, M. E.
Benowitz, N. L.
机构
[1] San Francisco Gen Hosp, Posit Hlth Program, Community Consortium, San Francisco, CA 94110 USA
[2] San Francisco Gen Hosp, Div Hematol Oncol, San Francisco, CA 94110 USA
[3] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA
[4] San Francisco Gen Hosp, Div Neurol, San Francisco, CA 94110 USA
[5] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA
[6] Univ Calif San Francisco, Div Clin Pharmacol & Expt Therapeut, San Francisco, CA 94143 USA
关键词
D O I
10.1038/sj.clpt.6100200
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
Although cannabis may have potential therapeutic value, inhalation of a combustion product is an undesirable delivery system. The aim of the study was to investigate vaporization using the Volcano (R) device as an alternative means of delivery of inhaled Cannabis sativa. Eighteen healthy inpatient subjects enrolled to compare the delivery of cannabinoids by vaporization to marijuana smoked in a standard cigarette. One strength (1.7, 3.4, or 6.8% tetrahydrocannabinol (THC)) and delivery system was randomly assigned for each of the 6 study days. Plasma concentrations of Delta-9-THC, expired carbon monoxide (CO), physiologic and neuropsychologic effects were the main outcome measures. Peak plasma concentrations and 6-h area under the plasma concentration-time curve of THC were similar. CO levels were reduced with vaporization. No adverse events occurred. Vaporization of cannabis is a safe and effective mode of delivery of THC. Further trials of clinical effectiveness of cannabis could utilize vaporization as a smokeless delivery system.
引用
收藏
页码:572 / 578
页数:7
相关论文
共 11 条
[1]
Short-term effects of cannabinoids in patients with HIV-1 infection - A randomized, placebo-controlled clinical trial [J].
Abrams, DI ;
Hilton, JF ;
Leiser, RJ ;
Shade, SB ;
Elbeik, TA ;
Aweeka, FT ;
Benowitz, NL ;
Bredt, BM ;
Kosel, B ;
Aberg, JA ;
Deeks, SG ;
Mitchell, TF ;
Mulligan, K ;
Bacchetti, P ;
McCune, JM ;
Schambelan, M .
ANNALS OF INTERNAL MEDICINE, 2003, 139 (04) :258-266
[2]
BENOWITZ NL, NCI SMOKING TOBACCO, V13, P39
[3]
Center for Drug Evaluation and Research, GUID IND BIOAV BIOEQ
[4]
POWER AND SAMPLE-SIZE CALCULATIONS - A REVIEW AND COMPUTER-PROGRAM [J].
DUPONT, WD ;
PLUMMER, WD .
CONTROLLED CLINICAL TRIALS, 1990, 11 (02) :116-128
[5]
Foltin R., 1988, APPETITE, V25, P577
[6]
GIERINGER D, 2001, J CANNABIS THER, V1, P3
[7]
Evaluation of a vaporizing device (Volcano®) for the pulmonary administration of tetrahydrocannabinol [J].
Hazekamp, Arno ;
Ruhaak, Renee ;
Zuurman, Lineke ;
Van Gerven, Joop ;
Verpoorte, Rob .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2006, 95 (06) :1308-1317
[8]
Hulley SB, 1988, DESIGNING CLIN RES
[9]
Joy J.E., 1999, Marijuana and medicine: assessing the science base
[10]
RUSSO E, 2003, J CANNABIS THER, V3, P67